ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa

Phase 3

Completed

Conditions: Acute Otitis Externa

Interventions: Other: AL-60371 Vehicle
Drug: AL-60371, 0.3% Otic Suspension

First Posted Date: 2012-02-20

Last Posted Date: 2014-07-08

Lead Sponsor: Alcon Research

Target Recruit Count: 768

Registration Number: NCT01535599

Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa

Phase 3

Completed

Conditions: Acute Otitis Externa

Interventions: Drug: AL-60371, 0.3% otic suspension
Drug: AL-60371 Vehicle

First Posted Date: 2012-02-17

Last Posted Date: 2013-12-10

Lead Sponsor: Alcon Research

Target Recruit Count: 589

Registration Number: NCT01535560

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Brinzolamide/timolol maleate fixed combination

First Posted Date: 2012-01-25

Last Posted Date: 2015-08-07

Lead Sponsor: Alcon Research

Target Recruit Count: 50

Registration Number: NCT01518244

VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery

Phase 3

Withdrawn

Conditions: Cataracts

Interventions: Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)

First Posted Date: 2012-01-24

Last Posted Date: 2014-03-26

Lead Sponsor: Alcon Research

Registration Number: NCT01515826

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Phase 4

Terminated

Conditions: Glaucoma

Interventions: Drug: Brinzolamide/timolol maleate fixed combination

First Posted Date: 2012-01-23

Last Posted Date: 2013-10-21

Lead Sponsor: Alcon Research

Target Recruit Count: 9

Registration Number: NCT01514734

Locations: 🇧🇷
Contact Alcon Call Center for Trial Locations, São Paulo, Brazil

Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

Phase 4

Terminated

Conditions: Glaucoma

Interventions: Drug: Travoprost/Timolol Maleate BAK-Free Fixed Combination

First Posted Date: 2012-01-23

Last Posted Date: 2014-12-03

Lead Sponsor: Alcon Research

Target Recruit Count: 37

Registration Number: NCT01514721

Locations: 🇧🇷
Alcon Investigational Site, Sao Paulo, Brazil

Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]

Not Applicable

Completed

Conditions: Cataracts

Interventions: Device: AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]
Device: AcrySof® IQ Monofocal IOL Model SN60WF

First Posted Date: 2012-01-16

Last Posted Date: 2015-05-27

Lead Sponsor: Alcon Research

Target Recruit Count: 409

Registration Number: NCT01510717

Travacom Post Marketing Surveillance Study

Phase 4

Withdrawn

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost/timolol fixed combination (Travacom)

First Posted Date: 2012-01-13

Last Posted Date: 2012-10-18

Lead Sponsor: Alcon Research

Registration Number: NCT01510132

Efficacy of Changing to TRAVATAN® From Prior Therapy

Phase 4

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004% BAK-free

First Posted Date: 2012-01-13

Last Posted Date: 2014-06-13

Lead Sponsor: Alcon Research

Target Recruit Count: 191

Registration Number: NCT01510145

Long Term Safety Protocol for the AcrySof CACHET Phakic Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: ACRYSOF CACHET Phakic Lens (L-series)

First Posted Date: 2011-12-22

Last Posted Date: 2019-07-02

Lead Sponsor: Alcon Research

Target Recruit Count: 657

Registration Number: NCT01497067

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy